| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a22000007a 4500 |
| 001 |
in00005774113 |
| 005 |
20260327180730.9 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
241111s2025 enk o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d N$T
|d OCLCO
|d OCLCQ
|d OCLCL
|d SFB
|
| 020 |
|
|
|a 0443334765
|q (electronic bk.)
|
| 020 |
|
|
|a 9780443334764
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443334757
|
| 035 |
|
|
|a (OCoLC)1467957548
|
| 050 |
|
4 |
|a RC280.C6
|
| 082 |
0 |
4 |
|a 616.99/4347061
|2 23/eng/20241120
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Colorectal cancer treatment resistance :
|b mechanisms, insights, advances and solutions /
|c edited by Zodwa Dlamini.
|
| 260 |
|
|
|a London, United Kingdom :
|b Academic Press,
|c 2025.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Includes index.
|
| 505 |
0 |
|
|a Front Cover -- Colorectal Cancer Treatment Resistance -- Copyright Page -- Contents -- List of contributors -- Preface -- Part 1: Understanding Colorectal Cancer Drug Resistance -- Part 2: Innovative Approaches to Overcoming Drug Resistance -- Part 3: Molecular Factors and Therapeutic Strategies -- Part 4: Future Perspectives and Advanced Research -- 1 Understanding colorectal cancer drug resistance -- 1 Unraveling the mystery of treatment resistance in colorectal cancer -- Abbreviations -- Introduction -- Drug resistance in colorectal cancer -- Future technologies in overcoming treatment resistance -- Overcoming treatment resistance -- Chemotherapy resistance -- Immunotherapy and immunomodulation in treatment resistance -- Targeting alternative splicing -- Nanomedicine -- ncRNA in reversing resistance in colorectal cancer -- Targeting genetic signatures in overcoming colorectal cancer resistance -- Surgical interventions -- Research advances in colorectal treatment resistance -- Microbes in colon cancer drug resistance -- Conclusion -- Conflicts of interest -- References -- 2 Mechanisms of treatment resistance in colorectal cancer -- Abbreviations -- Introduction -- Multifaceted mechanisms underlying treatment resistance -- Role of pharmacokinetics in the evolution of treatment resistance -- Increased drug excretion -- Drug target alteration -- DNA damage repair -- The role of tumor microenvironment stromal cells in the evolution of treatment-resistant colorectal cancer -- Mesenchymal stem cells -- Cancer-associated fibroblasts -- Immunosuppressive cells -- The role of adipocytes -- Why do certain therapies fail? -- Potential targets for intervention to overcome resistance -- Limitations -- Conclusion -- Conflict of interest -- References -- 3 Biomarkers and predictive factors in colorectal cancer treatment resistance -- Abbreviations.
|
| 505 |
8 |
|
|a Introduction -- Biomarkers in colorectal cancer diagnosis, prognosis, therapy, and response -- Diagnostic biomarkers in colorectal cancer -- Prognostic biomarkers in colorectal cancer -- Predictive biomarkers in colorectal cancer -- Predictive factors in colorectal cancer treatment resistance -- Hypermethylation -- Tumor microenvironment -- Other factors -- Colorectal cancer exposome and disparities -- Effects of ecosystems on colorectal cancer -- Lifestyles factors and colorectal cancer -- Social variables and colorectal cancer -- Advances and integrated approaches in colorectal cancer prognostic biomarker discovery -- Genomics -- Proteomics -- Metabolomics -- Multiomics approaches -- Challenges and limitations -- Conclusions -- Conflict of interest -- References -- 4 Targeted therapies and precision medicine in colorectal cancer drug resistance -- List of abbreviations -- Introduction -- Innovative approaches that tailor treatments to the unique genetic and molecular characteristics -- Ground-breaking advances in precision medicine and FDA-accepted targeted therapies -- Bevacizumab -- Cetuximab -- Panitumumab -- Ziv-Aflibercept -- Regorafenib -- Ramucirumab -- Pembrolizumab -- Nivolumab -- Ipilimumab -- Encorafenib -- Molecular pathways of colorectal cancer and potential targeted therapies -- Rat sarcoma-mutation targeted therapy -- Serine/threonine-protein kinase B-Raf mutation targeted therapy -- Microsatellite Instability targeted therapy -- Neurotrophic tyrosine receptor kinase gene fusion targeted therapy -- The role of phytochemical-based targeted therapy in colorectal cancer -- Combination therapy measures -- Limitations -- Conclusion -- Conflicts of interest -- References -- 2 Innovative approaches to overcoming drug resistance -- 5 Overcoming chemotherapy resistance in colorectal cancer -- Abbreviations.
|
| 505 |
8 |
|
|a Introduction into colorectal cancer -- Strategies to overcome chemotherapy resistance in colorectal cancer -- Medications and supplements -- Metformin -- Ivermectin -- Dichloroacetate -- Bazedoxifene -- Enalapril -- Melatonin -- Vitamins -- S-adenosylmethionine -- Nonsteroidal antiinflammatory drugs -- Gene therapy -- Ribozymes -- RNA interference -- Antisense oligonucleotides -- Clustered regularly interspaced short palindromic repeats -- Epigenetic therapy -- Noncoding RNAs -- Protein inhibitors -- Inhibitors of common resistance-related proteins -- Epidermal growth factor receptor inhibitors -- Sphingosine 1 phosphate receptor modulators -- Natural herbal compounds -- Innovative drug delivery system -- Liposomes -- Hydrogels -- Nanocarriers -- Exosomes -- Combinational therapy -- Supportive care measures -- Limitations -- Conclusion -- Conflict of Interest -- References -- 6 Emerging treatment approaches for colorectal cancer treatment resistance -- Abbreviations -- Introduction -- Targeted therapies -- Epidermal growth factor receptor inhibitors -- Antiangiogenic agents -- Human epidermal growth factor receptor 2-targeted therapies -- BRAF inhibitors -- Mismatch repair and microsatellite instability targeting -- PI3K/AKT/mTOR pathway inhibitors -- Wnt pathway inhibitors -- Human epidermal growth factor receptor 3-targeted therapies -- Immunotherapies -- Immune checkpoint inhibitors and the MSI-H/dMMR subset -- Expanding immunotherapy to microsatellite stable colorectal cancer -- Personalized vaccines and neoantigen targeting -- Chimeric antigen receptor T-cell therapy -- Bispecific antibodies and T-cell engagers -- Microbiome modulation and response to immunotherapy -- Combination therapies -- Personalized medicine strategies -- Limitations and outlook -- Conclusion -- Conflict of Interest -- References.
|
| 505 |
8 |
|
|a 7 Immunotherapy and immunomodulation in colorectal cancer treatment resistance -- Abbreviations -- Introduction -- Current immunotherapeutic strategies in metastatic colorectal cancer management -- Understanding immunotherapy resistance mechanisms in colorectal cancer -- Immunotherapy strategies for overcoming treatment resistance -- Overcoming resistance mechanisms -- Ten-eleven translocation 1 -- Ring-finger protein 43 -- Nuclear receptor coactivator 3 -- Large tumor suppressor -- Neurogenic locus notch homolog protein 3 -- Cyclic-AMP response element binding protein -- Remodeling the tumor microenvironment -- Combinational therapies and efforts to tailor therapy for individualized treatment -- Challenges and limitations -- Future directions and perspectives -- Opportunities in implementing innovative approaches and optimizing therapeutic outcomes -- Reshaping the landscape of colorectal cancer management -- Conclusion -- Conflict of Interest -- References -- 8 Splicing-associated drug resistance in colorectal cancer: targeting splicing signatures -- Abbreviations -- Introduction -- Alternate splicing events in colon cancer -- Cis regulatory elements -- Transregulatory factors in colorectal cancer -- Posttranslational alterations of transregulatory splicing factors -- Alternative splicing in drug resistance in colorectal cancer -- DNA damage response -- Resistance to apoptosis -- Invasion and metastasis -- Altering angiogenesis -- Targeting alternative splicing to reverse drug resistance -- Antisense oligonucleotides -- Therapeutic approaches of small molecule inhibitors -- Conclusion -- Conflict of Interest -- References -- 9 Nanomedicine innovations: conquering colorectal cancer drug resistance -- Introduction -- Mechanisms of drug resistance in colorectal cancer -- Mechanism of action of nanoparticles.
|
| 520 |
|
|
|a Colorectal Cancer Treatment Resistance: Mechanisms, Insights, Advances and Solutions provide insights, knowledge, and potential solutions for healthcare professionals, researchers, and individuals affected by colorectal cancer.
|
| 650 |
|
0 |
|a Colon (Anatomy)
|x Cancer
|x Treatment.
|
| 650 |
|
0 |
|a Rectum
|x Cancer
|x Treatment.
|
| 650 |
|
0 |
|a Drug resistance in cancer cells.
|
| 650 |
|
2 |
|a Drug Resistance, Neoplasm
|
| 650 |
|
6 |
|a Cellules cancéreuses
|x Résistance aux médicaments.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Dlamini, Zodwa.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780443334757
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 111da1f8-f0df-4e3b-b83a-d4b2c010dc85
|s a7bf3cc0-5a06-4c1f-8b37-8c8ee98879e1
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RC280.C6
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC280.C6
|t 0
|l Available Online
|